Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
8.8
%Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2023年4月1日〜2023年12月31日ConsolidatedIFRSNet Sales112,728¥ millionYear on year +2.6%Progress 76.7%
Operating profit30,450¥ millionYear on year +8.8%Progress 90.9%
Ordinary income30,973¥ millionYear on year +9.0%Progress 91.1%
Net income attributable to owners of the parent24,002¥ millionYear on year +5.9%Progress 92.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share356.37円
Financial position at period-end
Total assets247,830¥ million
of which net assets 215,316 ¥ millionEquity ratio 86.8%vs. prior year-end +4.4pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+8,126
Investment-2,654
Financials-9,046
Net change-3,574
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥57,323 million
Segment revenue¥94,606 million (YoY +1.6%), ¥18,121 million (YoY +7.7%)
Segment profit¥28,349 million, ¥1,230 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥147,000 million (YoY +2.0%)
Operating profit¥33,500 million (YoY +11.5%)
Ordinary income¥34,000 million (YoY +11.5%)
Net income¥26,000 million (YoY +14.0%)
Annual Dividend Forecast¥114 → ¥124（+8.8%）
Factors Behind Changes in Business Performance
増収と売上構成による売上原価率の低下等により営業利益が増加。医薬品事業では薬価改定や後発品の影響があったものの、ウプトラビ、海外売上に伴うロイヤリティ収入、ビルテプソ等が伸長し、機能食品事業ではプロテイン製剤、サプリメント等の売上が増加。
Disclosure regarding the going concern assumption
None ("There are no applicable matters.")
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew 0 companies (company name: —) / Excluded 0 companies (company name: —)
Depreciation and amortization¥3,695 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Conference call for institutional investors and securities analysts
Issued Shares at Period-End70,251,484 Shares
Treasury Shares at Period-End2,898,706 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年4月1日〜2023年12月31日 |
| Net Sales | ¥112,728 million (YoY +2.6%) |
| Operating profit | ¥30,450 million (YoY +8.8%) |
| Ordinary income | ¥30,973 million (YoY +9.0%) |
| Profit attributable to owners of the parent | ¥24,002 million (YoY +5.9%) |
| Net income per share | 356.37円 |
| Equity ratio | End of the current fiscal period 86.8 / End of previous period 82.4 |
| Total assets | ¥247,830 million |
| Net assets | ¥215,316 million |
| Cash flows from operating activities | ¥8,126 million |
| Cash flows from investing activities | ¥-2,654 million |
| Cash flows from financing activities | ¥-9,046 million |
| Cash and cash equivalents at end of period | ¥57,323 million |
| Full-year earnings forecast | Net Sales ¥147,000 million (YoY +2.0%) / Operating profit ¥33,500 million (YoY +11.5%) / Ordinary income ¥34,000 million (YoY +11.5%) / Net income ¥26,000 million (YoY +14.0%) |
| Annual Dividend Forecast | ¥114 → ¥124（+8.8%） |
| Segment revenue | ¥94,606 million (YoY +1.6%), ¥18,121 million (YoY +7.7%) |
| Segment profit | ¥28,349 million, ¥1,230 million |
| Depreciation and amortization | ¥3,695 million |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 0 companies (company name: —) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Conference call for institutional investors and securities analysts |
| Issued Shares at Period-End | 70,251,484 Shares |
| Treasury Shares at Period-End | 2,898,706 Shares |
| Factors Behind Changes in Business Performance | 増収と売上構成による売上原価率の低下等により営業利益が増加。医薬品事業では薬価改定や後発品の影響があったものの、ウプトラビ、海外売上に伴うロイヤリティ収入、ビルテプソ等が伸長し、機能食品事業ではプロテイン製剤、サプリメント等の売上が増加。 |
Items this document does not state (9)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.会社は、増収と売上構成による売上原価率の低下等により営業利益が増加したと説明している。医薬品事業ではウプトラビ、海外売上に伴うロイヤリティ収入、ビルテプソ等が伸長し、機能食品事業ではプロテイン製剤やサプリメント等の売上が増加した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.